Gilead presses forward with next-gen CAR-T, inking deal with small synthetic biology startup
Gilead is dipping its toes into some early-stage discovery work.
Through its subsidiary Kite Pharma, Gilead signed a deal with California biotech Refuge Biotechnologies to access a gene expression platform with the goal of developing cell therapies for blood cancers. No dollar amounts were disclosed, but Gilead said in a press release that the deal fits in its larger mission to create a “new generation” of CAR-Ts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.